Literature DB >> 35402212

Development and validation of a prognostic nomogram for Hürthle cell thyroid carcinoma: a SEER-based study.

Cong Shen1, Yunzhe Zhao1, Xiangyuan Qiu1, Peng Li1, Ying Ding1, Wenlong Wang1, Botao Sun1, Xinying Li1,2, Wei Jiang1,2.   

Abstract

Background: Hürthle cell carcinoma is a rare subtype of thyroid cancer, and its clinical behavior and biological characteristics remain unclear. This study aimed to establish nomogram models for the prognostic evaluation of Hürthle cell thyroid carcinoma (HCTC) in terms of both cancer-specific survival (CSS) and overall survival (OS).
Methods: Data for a total of 3,264 patients with HCTC (2004 to 2018) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox regression analysis was performed to identify significant predictors of prognosis and develop a prognostic nomogram. The performance of the model was assessed based on the area under the receiver operating characteristic curve (AUC), concordance index (c-index), and calibration curves.
Results: Multivariate Cox regression analysis showed that age, sex, summary stage, tumor size, N stage, M stage, and treatment with thyroidectomy were independent predictors of OS. Moreover, age, summary stage, tumor size, N stage, M stage, AJCC stage, and treatment with thyroidectomy were significantly correlated with CSS. The c-index of the OS and CSS nomograms developed based on these factors was 0.822 (95% CI: 0.803-0.841) and 0.893 (95% CI: 0.866-0.920), respectively. The AUC was 0.888, 0.841, and 0.834 for 1-, 3-, and 5-year OS and 0.970, 0.949, and 0.933 for 1-, 3-, and 5-year CSS, respectively. The calibration curves showed good agreement between observed and predicted values. Moreover, decision curve analysis revealed that the nomogram had a better clinical utility than individual clinicopathological markers. Conclusions: A prognostic nomogram that allows the individualized assessment of OS and CSS in HCTC was developed. This nomogram could be used to guide treatment decisions in patients with HCTC. 2022 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Hürthle cell carcinoma; Surveillance, Epidemiology, and End Results database (SEER database); cancer-specific survival (CSS); nomogram; overall survival (OS)

Year:  2022        PMID: 35402212      PMCID: PMC8984989          DOI: 10.21037/gs-21-781

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  30 in total

1.  Hurthle cell carcinoma: an update on survival over the last 35 years.

Authors:  Sapna Nagar; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Raymon H Grogan
Journal:  Surgery       Date:  2013-08-22       Impact factor: 3.982

2.  The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives.

Authors:  Kennichi Kakudo; Andrey Bychkov; Yanhua Bai; Yaqiong Li; Zhiyan Liu; Chan Kwon Jung
Journal:  Pathol Int       Date:  2018-12-07       Impact factor: 2.534

3.  Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hürthle cell carcinoma.

Authors:  Ander Ernaga Lorea; Iranzu Migueliz Bermejo; Emma Anda Apiñániz; Javier Pineda Arribas; Marta Toni García; Juan Pablo Martínez de Esteban; Ana María Insausti Serrano
Journal:  Endocrinol Diabetes Nutr (Engl Ed)       Date:  2018-02-09       Impact factor: 1.417

4.  Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.

Authors:  Ian Ganly; Julio Ricarte Filho; Stephanie Eng; Ronald Ghossein; Luc G T Morris; Yupu Liang; Nicholas Socci; Kasthuri Kannan; Qianxing Mo; James A Fagin; Timothy A Chan
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

Review 5.  Management of follicular and Hürthle cell neoplasms of the thyroid gland.

Authors:  C R McHenry; B A Sandoval
Journal:  Surg Oncol Clin N Am       Date:  1998-10       Impact factor: 3.495

6.  Survival and prognosis in Hürthle cell carcinoma of the thyroid gland.

Authors:  Neil Bhattacharyya
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-02

7.  Age and tumor size predicts lymph node involvement in Hürthle Cell Carcinoma.

Authors:  Marlon A Guerrero; Insoo Suh; Menno R Vriens; Wen T Shen; Jessica Gosnell; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  J Cancer       Date:  2010-06-02       Impact factor: 4.207

Review 8.  Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management.

Authors:  Giorgio Grani; Livia Lamartina; Cosimo Durante; Sebastiano Filetti; David S Cooper
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-05       Impact factor: 32.069

9.  Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003.

Authors:  S C Mills; M Haq; W J B Smellie; C Harmer
Journal:  Eur J Surg Oncol       Date:  2008-08-21       Impact factor: 4.424

10.  Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience.

Authors:  Branisav Oluic; Ivan Paunovic; Zlatibor Loncar; Vladimir Djukic; Aleksandar Diklic; Milan Jovanovic; Zeljko Garabinovic; Nikola Slijepcevic; Branislav Rovcanin; Dusan Micic; Aleksandar Filipovic; Vladan Zivaljevic
Journal:  BMC Cancer       Date:  2017-05-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.